Home - Gene Surgery

We are developing gene therapeutics for cancer treatmen

Our company

“Gene Surgery” LLC is a preclinical and clinical stage biotechnology company focused on the development of anti-tumoral gene therapeutics

Our mission

our company

Our mission

To preserve and extend quality life for cancer patients using genetic technologies.

Pipeline

The pipeline reflects our team’s commitment to using advances in gene therapy to create new opportunities in the treatment of solid tumors

Drug candidate

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Market

AntioncoRAN-M (Stimotimagen copolimerplasmid)

Solid tumors

Drug candidate

Stimotimagen copolimerplasmid is an antitumoral gene therapeutic comprised of two components:

Component A

Therapeutic
plasmid DNA

Component B

Polycationic
polymer

Mechanism of action

Stimotimagen copolimerplasmid

Non-viral
delivery system

Polymeric envelope – forms the nanoparticles with therapeutic DNA capable of intracellular entry

GM-CSF

Human granulocyte-macrophage colony-stimulating factor gene. The gene product stimulates proliferation and differentiation of antigen-presenting cells. As a result, the antitumour immune response is activated

HSVtk

The herpes simplex virus thymidine kinase gene. The gene product converts the prodrug (ganciclovir) into a toxin. As a result, the tumor cells die

Ganciclovir
pro-drug

Gene delivery system

PEI

Polyethylenimine

Polyplex
nanoparticle
formation

PEG

Polyethylene glycol

TAT-peptide

Facilitates the entry of the nanoparticles into cells

DNA

Plasmid DNA

Encodes therapeutic genes

PEG-PEI-TAT complex has the ability to package DNA and protect it from the action of DNAases, providing stability of the drug.

Treatment scheme

Triple intratumoral administration of Stimotimagen copolymerplasmid at 5-day intervals

Days

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

intravenous administration of the prodrug ganciclovir twice daily, 12 hours apart